6763 related articles for article (PubMed ID: 2566177)
1. Low doses of chemotherapy to inhibit suppressor T cells.
Berd D
Prog Clin Biol Res; 1989; 288():449-58. PubMed ID: 2566177
[No Abstract] [Full Text] [Related]
2. [Development in the immunotherapy of malignant melanoma].
Tritsch H
Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
[TBL] [Abstract][Full Text] [Related]
3. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.
Berd D; Mastrangelo MJ
Cancer Res; 1988 Mar; 48(6):1671-5. PubMed ID: 2830969
[TBL] [Abstract][Full Text] [Related]
4. Experience gained in immunotherapy from the immunopharmacology of BCG leading to a second generation of systemic immunity adjuvants.
Mathe G
Comp Immunol Microbiol Infect Dis; 1980; 3(4):407-32. PubMed ID: 6451350
[No Abstract] [Full Text] [Related]
5. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
6. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.
Berd D; Maguire HC; Mastrangelo MJ
Cancer Res; 1986 May; 46(5):2572-7. PubMed ID: 3697996
[TBL] [Abstract][Full Text] [Related]
7. Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses.
Berd D; Sato T; Mastrangelo MJ
Cancer Immunol Immunother; 2002 Aug; 51(6):320-6. PubMed ID: 12111120
[TBL] [Abstract][Full Text] [Related]
8. [Clinical trial of immunotherapy for cancer].
Adler A; Stein JA; Maor M
Harefuah; 1972 Dec; 83(12):513-7. PubMed ID: 4659015
[No Abstract] [Full Text] [Related]
9. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.
Smithers M; O'Connell K; MacFadyen S; Chambers M; Greenwood K; Boyce A; Abdul-Jabbar I; Barker K; Grimmett K; Walpole E; Thomas R
Cancer Immunol Immunother; 2003 Jan; 52(1):41-52. PubMed ID: 12536239
[TBL] [Abstract][Full Text] [Related]
10. Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo.
Delgado M; Chorny A; Gonzalez-Rey E; Ganea D
J Leukoc Biol; 2005 Dec; 78(6):1327-38. PubMed ID: 16204628
[TBL] [Abstract][Full Text] [Related]
11. Active specific immunotherapy in malignant melanoma.
Morton DL; Foshag LJ; Nizze JA; Gupta RK; Famatiga E; Hoon DS; Irie RF
Semin Surg Oncol; 1989; 5(6):420-5. PubMed ID: 2531908
[TBL] [Abstract][Full Text] [Related]
12. Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look.
Bluming AZ; Vogel CL; Ziegler JL; Kiryabwire JW
J Natl Cancer Inst; 1972 Jan; 48(1):17-24. PubMed ID: 4652371
[No Abstract] [Full Text] [Related]
13. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
[TBL] [Abstract][Full Text] [Related]
14. Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy.
Tian B; Hao J; Zhang Y; Tian L; Yi H; O'Brien TD; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2009 Jan; 87(2):198-206. PubMed ID: 19155973
[TBL] [Abstract][Full Text] [Related]
15. Active specific immunotherapy in the treatment of human cancers.
Mitchell MS
Prog Clin Biol Res; 1989; 288():323-36. PubMed ID: 2524071
[No Abstract] [Full Text] [Related]
16. [Characteristics of T-suppressors responsible for the competition between cellular and humoral immune response in the spleen].
Gusev EIu; Kevorkov NN
Biull Eksp Biol Med; 1993 Mar; 115(3):287-9. PubMed ID: 8054627
[TBL] [Abstract][Full Text] [Related]
17. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
Berd D; Mastrangelo MJ
Cancer Invest; 1988; 6(3):337-49. PubMed ID: 3167614
[TBL] [Abstract][Full Text] [Related]
18. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
[TBL] [Abstract][Full Text] [Related]
19. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.
Mitchell MS; Kan-Mitchell J; Kempf RA; Harel W; Shau HY; Lind S
Cancer Res; 1988 Oct; 48(20):5883-93. PubMed ID: 3262416
[TBL] [Abstract][Full Text] [Related]
20. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]